Jane Street Group LLC bought a new position in Silk Road Medical Inc (NASDAQ:SILK) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,433 shares of the company’s stock, valued at approximately $263,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SILK. Bank of Montreal Can acquired a new stake in Silk Road Medical in the second quarter worth approximately $28,000. Elkfork Partners LLC acquired a new stake in Silk Road Medical in the second quarter worth approximately $30,000. Meadow Creek Investment Management LLC acquired a new stake in Silk Road Medical in the second quarter worth approximately $36,000. FNY Investment Advisers LLC acquired a new stake in Silk Road Medical in the second quarter worth approximately $70,000. Finally, Advisor Group Inc. acquired a new stake in Silk Road Medical in the second quarter worth approximately $78,000. Hedge funds and other institutional investors own 70.18% of the company’s stock.
NASDAQ SILK opened at $31.15 on Friday. Silk Road Medical Inc has a 1 year low of $27.83 and a 1 year high of $51.50. The firm has a fifty day moving average of $36.28. The company has a current ratio of 14.32, a quick ratio of 13.38 and a debt-to-equity ratio of 0.53.
In other Silk Road Medical news, major shareholder Pincus & Co. Warburg sold 630,000 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $39.50, for a total value of $24,885,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Several research firms have issued reports on SILK. Zacks Investment Research cut Silk Road Medical from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. Argus began coverage on Silk Road Medical in a report on Tuesday, August 20th. They issued a “buy” rating and a $52.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $45.00.
Silk Road Medical Profile
Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.
Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.